查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1407306

复合化疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、癌症类型、配销通路、地区和竞争细分

Compounding Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drug Type, By Route of Administration, By Cancer Type, By Distribution Channel, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球复合化疗市场价值为 50.7 亿美元，预计到 2028 年，预测期内将出现令人印象深刻的增长，年CAGR为5.08%。复合化疗是指根据个人需求製备客製化化疗药物的专业实践的癌症患者。这个过程是透过将药房或医疗机构与必要的专业知识、设备和基础设施结合起来来完成的。复合化疗药物可以製备成多种剂型，例如口服溶液、胶囊、外用乳膏、栓剂和静脉（IV）製剂。剂型的选择取决于患者的医疗需求、偏好以及治疗计划的特定要求。复合化疗对于可能有独特剂量要求或吞嚥常规药片或胶囊有困难的儿科和老年患者特别有价值。可以设计复合製剂来满足这些人群的特定需求。

肿瘤学向个人化医疗的转变推动了对复合化疗的需求。复合药物允许医疗保健提供者根据个别患者的情况（包括遗传和分子特征）量身定制治疗方案。持续的研究和开发工作导致了新化疗药物和联合疗法的发现。复方药局在製备和供应这些临床使用的创新药物方面发挥着至关重要的作用。复合化疗通常对于治疗罕见癌症和孤儿癌症至关重要，因为标准化治疗方案可能不可用或无效。管理化疗相关副作用和提供支持性护理的重要性日益增加。止吐药和止痛药等复方药物对于提高治疗期间患者的舒适度至关重要。早期癌症检测和筛检计划导致了癌症的早期诊断，增加了对化疗药物和复合治疗的需求。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 50.7亿美元
2028 年市场规模 67.7亿美元
2023-2028 年CAGR 5.08%
成长最快的细分市场 网路药局
最大的市场 北美洲

药物开发的进展

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（细胞毒性药物、荷尔蒙药物、免疫调节剂、标靶治疗、支持性治疗药物）
    • 依给药途径（静脉注射、口服、皮下、肌肉内、鞘内）
    • 依癌症类型（乳癌、肺癌、大肠癌、摄护腺癌、白血病、淋巴瘤等）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按癌症类型
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按癌症类型
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按癌症类型
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按癌症类型
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲复合化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 依给药途径
    • 按癌症类型
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非复合化疗
    • 沙乌地阿拉伯复合化疗
    • 阿联酋复合化疗

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 辉瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 百特国际公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 格里福斯公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 科塞斯SPA
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 阿克西姆公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 迪达勒斯集团
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 贝朗梅尔松根股份公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Omnicell 技术公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 麦特里克斯公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 斯特林有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 16 章：策略建议

简介目录
Product Code: 20591

Global Compounding Chemotherapy Market has valued at USD 5.07 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.08 % through 2028. Compounding chemotherapy refers to the specialized practice of preparing customized chemotherapy medications tailored to the individual needs of cancer patients. This process is carried out by compounding pharmacies or healthcare facilities with the necessary expertise, equipment, and infrastructure. Compounded chemotherapy medications can be prepared in various dosage forms, such as oral solutions, capsules, topical creams, suppositories, and intravenous (IV) formulations. The choice of dosage form depends on the patient's medical needs, preferences, and the specific requirements of the treatment plan. Compounding chemotherapy is particularly valuable for pediatric and geriatric patients who may have unique dosing requirements or difficulty swallowing conventional pills or capsules. Compounded formulations can be designed to meet the specific needs of these populations.

The shift towards personalized medicine in oncology has driven the demand for compound chemotherapy. Compounded drugs allow healthcare providers to tailor treatment regimens to individual patient profiles, including genetic and molecular characteristics. Ongoing research and development efforts have led to the discovery of new chemotherapy agents and combination therapies. Compounding pharmacies play a crucial role in preparing and supplying these innovative drugs for clinical use. Compounding chemotherapy is often essential for treating rare and orphan cancers, where standardized treatment options may not be available or effective. The importance of managing chemotherapy-related side effects and providing supportive care has grown. Compounded medications, such as antiemetics and pain management drugs, are crucial in enhancing patient comfort during treatment. Early cancer detection and screening programs have led to the diagnosis of cancer at earlier stages, increasing the demand for chemotherapy drugs and compounded treatments.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.07 Billion
Market Size 2028USD 6.77 Billion
CAGR 2023-20285.08%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Advancements in Drug Development

Targeted therapies have revolutionized cancer treatment by specifically targeting molecules or pathways involved in cancer growth. These therapies are designed to be more selective in attacking cancer cells while sparing healthy ones. Compounded chemotherapy drugs now include a range of targeted agents tailored to individual patient profiles. Immunotherapy drugs, such as immune checkpoint inhibitors, have emerged as a promising approach to cancer treatment. These drugs harness the patient's immune system to recognize and attack cancer cells. Compounding pharmacies prepare these immunotherapies for administration, contributing to their widespread use. The development and approval of biosimilar versions of some chemotherapy agents have increased access to these treatments while reducing costs. Compounding pharmacies may be involved in preparing and supplying biosimilars, ensuring their availability. Nanoparticle-based chemotherapy formulations have been developed to improve drug delivery and enhance the therapeutic index of chemotherapy agents. These nanocarriers can target cancer cells more precisely and reduce side effects. Compounding pharmacies are involved in preparing these advanced formulations. Liposomal encapsulation is a drug delivery technique that involves enclosing chemotherapy drugs in liposomes (tiny fat bubbles). This approach improves drug solubility, extends drug circulation in the body, and enhances drug delivery to tumor sites. Compounded liposomal chemotherapy formulations are increasingly used. Ongoing research efforts continue to identify new chemotherapy agents, combination therapies, and treatment regimens. Compounding pharmacies play a pivotal role in preparing and supplying these innovative drugs for clinical use and research purposes.

The emphasis on personalized medicine has led to the development of chemotherapy agents that target specific genetic mutations or molecular markers in cancer. Compounded chemotherapy drugs allow healthcare providers to tailor treatments to individual patient needs. Compounding chemotherapy is often essential for treating rare and orphan cancers for which standardized treatment options may not exist. Advances in orphan drug development have expanded the range of compound treatments available. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have accelerated the approval process for some cancer drugs, particularly those showing promising results in early clinical trials. Compounded drugs may play a role in providing patients with access to these therapies. The development of combination therapies involving multiple chemotherapy agents or a combination of chemotherapy with targeted or immunotherapies has become more common. Compounded chemotherapy regimens are designed to optimize treatment outcomes. Advances in pharmacogenomics allow healthcare providers to tailor chemotherapy treatments based on an individual's genetic makeup. Compounded chemotherapy regimens can be customized to match patients' genetic profiles. Compounded medications for managing chemotherapy-related side effects, such as antiemetics, pain management drugs, and growth factors, have improved patient comfort and adherence to treatment plans. This factor will help in the development of the Global Compounding Chemotherapy Market.

Evolving Treatment of Rare Cancers

Many rare cancers lack well-established standard treatment protocols due to their low incidence. Consequently, there may be a limited selection of commercially available chemotherapy drugs specifically approved for these rare cancer types. The emphasis on personalized medicine and patient-centric care has led to an increased interest in tailoring treatments to individual patients. For rare cancers, customized chemotherapy regimens are often necessary to address the unique characteristics of each patient's disease. In the absence of FDA-approved treatments for rare cancers, healthcare providers may turn to off-label use of existing chemotherapy drugs. Compounding pharmacies can prepare these drugs in appropriate formulations and dosages to meet the specific needs of patients with rare cancers. Many rare cancer patients participate in clinical trials to access experimental treatments. Compounded chemotherapy drugs are often used in clinical trial settings, contributing to the demand for compounding services. Some rare cancers are designated as orphan diseases, leading to specialized drug development efforts. Compounded medications may be an essential component of these orphan drug treatments.

The variability in how rare cancers respond to treatment necessitates flexibility in drug preparation and dosing. Compounding allows for the precise adjustment of chemotherapy regimens based on patient response. Compounding pharmacies can prepare specialized formulations, such as liposomal or nanoparticle-based chemotherapy, which may be particularly beneficial in treating rare cancers with unique characteristics. Patient advocacy groups for rare cancers often advocate for the development and availability of tailored treatments. Compounding allows for a personalized approach aligned with the goals of these advocacy efforts. The customization of chemotherapy treatments through compounding can lead to better treatment outcomes for individuals with rare cancers, as it considers factors such as the cancer's genetic profile and patient-specific characteristics. Oncologists and healthcare providers who specialize in rare cancers may have extensive experience in developing and implementing compounding-based treatment plans for their patients. This factor will pace up the demand of the Global Compounding Chemotherapy Market.

Rise in Supportive Oncology Care

Chemotherapy often leads to various side effects, such as nausea, vomiting, pain, and immune system suppression. Compounded medications, including antiemetics, analgesics, and supportive medications, are essential for managing these side effects and improving patient comfort and adherence to treatment plans. Supportive oncology care is highly patient-centric and aims to address each patient's unique needs and preferences. Compounded chemotherapy allows for personalized treatment regimens that consider individual patient profiles and tailor supportive medications accordingly. Some patients may be more susceptible to adverse reactions or allergies to commercially available chemotherapy drugs. Compounding pharmacies can prepare alternative formulations or adjust drug components to reduce the risk of such reactions. For patients with advanced or incurable cancers, palliative care focuses on improving the quality of life. Compounded chemotherapy may be part of palliative care regimens to manage symptoms and discomfort associated with cancer progression. Chemotherapy regimens can be challenging to tolerate for some patients, especially those with weakened immune systems or pre-existing health conditions. Compounded supportive medications, such as growth factors and antibiotics, can help patients better tolerate and complete their treatment. Supportive care often requires flexibility in dosing and administration of medications to address the changing needs of patients during their cancer journey. Compounding allows for precise dosing adjustments.

Compounding pharmacies can prepare specialized formulations, such as sustained-release or transdermal preparations, for certain supportive medications. These formulations may offer more convenient and effective delivery methods. Chemotherapy can lead to complications such as infections or anemia. Compounded medications, including antibiotics and blood-supporting drugs, are crucial in managing these complications and reducing the risk of treatment interruptions. Compounding pharmacists collaborate closely with oncologists and other members of the healthcare team to optimize supportive care plans. This teamwork ensures that patients receive comprehensive care that addresses both the cancer itself and the side effects of treatment. Supportive oncology care is aimed at enhancing patients' overall well-being during cancer treatment. Compounded medications contribute to patient comfort and can improve their overall quality of life. Improved management of chemotherapy-related side effects through supportive care can enhance patient adherence to treatment plans, ultimately leading to better treatment outcomes. This factor will accelerate the demand of the Global Compounding Chemotherapy Market.

Key Market Challenges

Quality Control and Safety

Compounded medications, including chemotherapy drugs, must adhere to strict regulatory guidelines and standards set by government agencies like the U.S. Food and Drug Administration (FDA) in the United States. Compliance with these regulations is critical to ensure the safety and efficacy of compounded drugs. Maintaining consistent quality in compounded chemotherapy drugs is challenging due to variations in raw materials, compounding processes, and equipment. Quality control measures must be in place to ensure that each batch of compounded medication meets established standards. Chemotherapy drugs are typically administered intravenously, which necessitates strict sterility measures during compounding. Contamination can lead to severe infections and adverse patient outcomes. Maintaining sterility is a constant concern. Cross-contamination is a risk when multiple chemotherapy drugs are compounded in the same facility. Stringent cleaning and sanitation procedures are essential to prevent unintended mixing of drugs and contamination. Precise dosing is critical in chemotherapy to achieve the desired therapeutic effect while minimizing side effects. Variability in dosing can lead to treatment failures or toxicity. Ensuring the accuracy of compounded doses is challenging but essential. Some chemotherapy drugs are chemically unstable and can degrade over time. Compounding pharmacies must monitor and manage drug stability to ensure that patients receive medications with the intended potency and efficacy.

Rising Healthcare Costs

Compounded chemotherapy drugs can be more expensive to prepare compared to commercially manufactured drugs due to the customization, specialized equipment, and quality control measures involved. This can add to the overall cost of cancer treatment. Meeting regulatory requirements and quality control standards, as mentioned earlier, can be costly. Compounding pharmacies must invest in infrastructure, training, and ongoing compliance efforts, which can increase operating costs. High healthcare costs, including the cost of chemotherapy, can pose a barrier to patient access. Some patients may face financial challenges in accessing compounded medications, especially if their insurance coverage does not fully cover the expenses. Reimbursement for compounded chemotherapy drugs can vary based on factors like insurance policies, healthcare provider contracts, and regional variations. Some compounded medications may not be fully reimbursed, leading to financial burdens for patients. Healthcare systems and institutions need to allocate resources efficiently to manage the increasing costs of cancer care, including the use of compounded chemotherapy. Balancing the need for personalized treatment with cost considerations is a complex challenge. Compounding pharmacies must invest in specialized equipment, cleanrooms, and quality control measures to ensure the safety and quality of compounded chemotherapy drugs. These investments can be substantial and contribute to higher costs.

Key Market Trends

Rising Interest in Sterile Compounding

Sterile compounding is essential for chemotherapy drugs, which are often administered intravenously or directly into the bloodstream. Ensuring sterility prevents the risk of infections and other complications, which can be life-threatening for cancer patients with compromised immune systems. Many chemotherapy drugs are potent and require precise dosing and administration. Sterile compounding allows for the accurate preparation of these drugs to minimize the risk of dosage errors. Sterile compounding facilitates the customization of chemotherapy regimens based on individual patient profiles, including cancer type, stage, and medical history. This personalized approach aligns with the trend toward precision medicine. The development of advanced drug delivery methods, such as nanoparticle-based formulations and liposomal encapsulation, has increased the demand for sterile compounding. These delivery systems require aseptic preparation. The focus on patient-centered care in oncology emphasizes providing treatments that are safe, effective, and tailored to individual patient needs. Sterile compounding supports this approach by ensuring the highest standards of safety and quality.

Segmental Insights

Drug Type Insights

In 2022, the Global Compounding Chemotherapy Market largest share was held by Immunomodulatory Agents segment in 2022. Immunomodulatory agents have shown significant efficacy in the treatment of various cancers, including hematologic malignancies and solid tumors. They work by modulating the immune system to recognize and attack cancer cells, making them a crucial component of many cancer treatment regimens. Immunotherapy, including immunomodulatory agents, has gained substantial attention in the field of oncology due to its potential to offer durable responses and fewer side effects compared to traditional chemotherapy. As a result, there has been an increased demand for compounded immunomodulatory agents. Many immunomodulatory agents are considered targeted therapies, as they specifically target molecules or pathways involved in cancer growth and immune evasion. This targeted approach enhances their effectiveness and minimizes damage to healthy cells.

Route of Administration Insights

In 2022, the Global Compounding Chemotherapy Market largest share was held by Intravenous (IV) segment in 2022. The IV route allows for the direct and rapid delivery of chemotherapy drugs into the bloodstream. This method ensures that the medication quickly reaches its target, which is particularly important for aggressive and fast-growing cancers. IV administration allows for precise dosing of chemotherapy drugs, ensuring that patients receive the correct amount of medication tailored to their specific needs. This precision is vital in cancer treatment, where even small variations in dosage can have significant effects on the patient's outcome. Intravenous chemotherapy can be used to treat a wide range of cancer types, including hematologic malignancies, solid tumors, and metastatic diseases. It is a versatile route of administration suitable for various chemotherapy agents. Many cancer patients are diagnosed at advanced stages when the disease has spread throughout the body. IV chemotherapy is well-suited for treating these advanced and metastatic cancers, making it a critical choice for a significant portion of patients.

Cancer Type Insights

In 2022, the Global Compounding Chemotherapy Market largest share was held by Lung Cancer segment in 2022. Lung cancer is one of the most common cancer types globally, with a significant incidence rate. This high prevalence of lung cancer contributes to a substantial demand for chemotherapy treatments, including compounded medications. Lung cancer is often treated using chemotherapy in combination with other treatment modalities, such as surgery, radiation therapy, and targeted therapy. Chemotherapy plays a central role in the management of both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), covering a broad spectrum of lung cancer cases. It is frequently diagnosed at advanced stages when the disease has spread (metastasized) beyond the lungs. In such cases, chemotherapy is commonly used to control the disease and improve patient outcomes, making it a vital component of treatment. Lung cancer treatment often requires a personalized approach. Compounded chemotherapy drugs allow healthcare providers to tailor treatment regimens to individual patient needs, considering factors like the cancer subtype, stage, genetic markers, and patient-specific characteristics.

Distribution Channel Insights

In 2022, the Global Compounding Chemotherapy Market was dominated by Hospital Pharmacies segment. Hospitals are primary healthcare institutions where a significant portion of cancer patients receive treatment, including chemotherapy. Hospital pharmacies are integral to the healthcare ecosystem, providing a wide range of medications, including compounded chemotherapy drugs, to inpatients and outpatients. Hospitals offer comprehensive medical care, including surgery, radiation therapy, and chemotherapy. This allows them to provide complete cancer care under one roof, and hospital pharmacies play a crucial role in ensuring the availability of chemotherapy medications tailored to individual patient needs. Many hospitals have specialized oncology departments staffed by oncologists and oncology pharmacists who are well-versed in the complexities of cancer treatment, including chemotherapy. This expertise is essential for compounding and administering chemotherapy safely and effectively.

Regional Insights

The North America region has established itself as the leader in the Global Compounding Chemotherapy Market in 2022. North America, particularly the United States and Canada, boasts advanced healthcare infrastructure, including well-established hospitals, clinics, and compounding facilities. This infrastructure supports the development, production, and delivery of compounded chemotherapy drugs. The region is a hub for pharmaceutical research and innovation, with numerous academic institutions, research centers, and pharmaceutical companies conducting cutting-edge research in oncology and drug development. This fosters the development of new chemotherapy drugs and compounding techniques. North America has a substantial population, and unfortunately, cancer rates are relatively high. The large patient pool creates a significant demand for chemotherapy drugs, including compounded formulations tailored to individual patient needs.

Key Market Players

Pfizer Inc.

Baxter International Inc.

Grifols SA

Comecer S.P.A.

Arxium Inc.

Dedalus Group

B. Braun Melsungen AG

Omnicell Technologies Inc.

The Metrix Company

Sterline S.R.L

Report Scope:

In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Chemotherapy Market, By Drug Type:

  • Cytotoxic Drugs
  • Hormonal Agents
  • Immunomodulatory Agents
  • Targeted Therapies
  • Supportive Care Drugs

Compounding Chemotherapy Market, By Route of Administration:

  • Intravenous
  • Oral
  • Subcutaneous
  • Intramuscular
  • Intrathecal

Compounding Chemotherapy Market, By Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia
  • Lymphoma
  • Others

Compounding Chemotherapy Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Compounding Chemotherapy Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.

Available Customizations:

  • Global Compounding Chemotherapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounding Chemotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
    • 5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
    • 5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Others)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Compounding Chemotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Cancer Type
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Compounding Chemotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Cancer Type
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Mexico Compounding Chemotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Cancer Type
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Canada Compounding Chemotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Cancer Type
        • 6.3.3.2.4. By Distribution Channel

7. Europe Compounding Chemotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Cancer Type
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Compounding Chemotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Cancer Type
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Germany Compounding Chemotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Cancer Type
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Cancer Type
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Compounding Chemotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Cancer Type
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Compounding Chemotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Cancer Type
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Compounding Chemotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Cancer Type
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Compounding Chemotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Cancer Type
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Compounding Chemotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Cancer Type
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. South Korea Compounding Chemotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Cancer Type
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Japan Compounding Chemotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Cancer Type
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Compounding Chemotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Cancer Type
        • 8.3.5.2.4. By Distribution Channel

9. South America Compounding Chemotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Cancer Type
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Compounding Chemotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Cancer Type
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Compounding Chemotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Cancer Type
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Compounding Chemotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Cancer Type
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Compounding Chemotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Cancer Type
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Compounding Chemotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Cancer Type
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Compounding Chemotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Cancer Type
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Compounding Chemotherapy market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Cancer Type
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed companies)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Baxter International Inc.
    • 15.2.1. Business Overview
    • 15.2.2. Company Snapshot
    • 15.2.3. Products & Services
    • 15.2.4. Financials (In case of listed companies)
    • 15.2.5. Recent Developments
    • 15.2.6. SWOT Analysis
  • 15.3. Grifols SA
    • 15.3.1. Business Overview
    • 15.3.2. Company Snapshot
    • 15.3.3. Products & Services
    • 15.3.4. Financials (In case of listed companies)
    • 15.3.5. Recent Developments
    • 15.3.6. SWOT Analysis
  • 15.4. Comecer S.P.A.
    • 15.4.1. Business Overview
    • 15.4.2. Company Snapshot
    • 15.4.3. Products & Services
    • 15.4.4. Financials (In case of listed companies)
    • 15.4.5. Recent Developments
    • 15.4.6. SWOT Analysis
  • 15.5. Arxium Inc.
    • 15.5.1. Business Overview
    • 15.5.2. Company Snapshot
    • 15.5.3. Products & Services
    • 15.5.4. Financials (In case of listed companies)
    • 15.5.5. Recent Developments
    • 15.5.6. SWOT Analysis
  • 15.6. Dedalus Group
    • 15.6.1. Business Overview
    • 15.6.2. Company Snapshot
    • 15.6.3. Products & Services
    • 15.6.4. Financials (In case of listed companies)
    • 15.6.5. Recent Developments
    • 15.6.6. SWOT Analysis
  • 15.7. B. Braun Melsungen AG
    • 15.7.1. Business Overview
    • 15.7.2. Company Snapshot
    • 15.7.3. Products & Services
    • 15.7.4. Financials (In case of listed companies)
    • 15.7.5. Recent Developments
    • 15.7.6. SWOT Analysis
  • 15.8. Omnicell Technologies Inc.
    • 15.8.1. Business Overview
    • 15.8.2. Company Snapshot
    • 15.8.3. Products & Services
    • 15.8.4. Financials (In case of listed companies)
    • 15.8.5. Recent Developments
    • 15.8.6. SWOT Analysis
  • 15.9. The Metrix Company
    • 15.9.1. Business Overview
    • 15.9.2. Company Snapshot
    • 15.9.3. Products & Services
    • 15.9.4. Financials (In case of listed companies)
    • 15.9.5. Recent Developments
    • 15.9.6. SWOT Analysis
  • 15.10. Sterline S.R.L.
    • 15.10.1. Business Overview
    • 15.10.2. Company Snapshot
    • 15.10.3. Products & Services
    • 15.10.4. Financials (In case of listed companies)
    • 15.10.5. Recent Developments
    • 15.10.6. SWOT Analysis

16. Strategic Recommendations